4-(9-(3,3-DIFLUOROCYCLOPENTYL)-5,7,7-TRIMETHYL-6-OXO-6,7,8,9-TETRAHYDRO-5H-PYRIMIDO[4,5-B[1,4]DIAZEPIN-2-YLAMINO)-3-METHOXYBENZAMIDE DERIVATIVES AS INHIBITORS OF THE HUMAN PROTEIN KINASES PLK1 TO PLK4 FOR THE TREATMENT OF PROLIFERATIVE DISEASES
Compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of PLK1 protein kinases. These compounds have the formula I, as defined herein or pharmaceutically acceptable salts thereof. These compounds, and pharmaceutically acceptable salts thereof, are useful for treating or preventing a variety of diseases, disorders or conditions, including, but not limited to, an autoimmune, inflammatory, proliferative, or hyperproliferative disease, a neurodegenerative disease, or an immunologically-mediated disease. Formula I wherein R1 is (formula) R6 is C1-4 aliphatic or C3-6 cycloaliphatic, and is optionally substituted with 1 or 2 halogen atoms X is O and R2 is -CH3 or X is NR5 and, R2 and R5, together with the atoms to which they are attached, form a 1,2,4-triazole each of R3 and R4 is independently H, methyl, or ethyl or R3 and R4, together with the atoms to which they are attached, form a cyclopropyl ring and n is 0 or 1.Cette invention se rapporte à des composés utilisés comme inhibiteurs de protéines kinases. Linvention concerne par ailleurs des compositions pharmaceutiquement acceptables comprenant lesdits composés et des procédés dutilisation des compositions dans le traitement de différentes maladies, différentes affections ou différents troubles.
